Angel Plus China
VC Fund
Beijing, China
Angel Plus China is a VC fund in Beijing focused on Software and Artificial Intelligence. Angel Plus is a China-based venture capital firm.
- Total investments:
- 86
- Last investment:
- Lead investor:
- 24%
Last updated:
For AI agents: llms.txt
Industries Angel Plus China invests in
Stages Angel Plus China invests in
Countries Angel Plus China invests in
Round sizes
Round size
- Seed
- $71k–$120M
- Angel
- $425k–$2.8M
- Series A
- $1.4M–$16M
Investment Focus
Industry
- Software 12 (14%)
- Artificial Intelligence 12 (14%)
- Information Technology 10 (12%)
- Health Care 9 (10%)
- Internet 8 (9%)
Stage
- Angel 40 (47%)
- Series A 20 (23%)
- Seed 11 (13%)
- Series B 6 (7%)
- Series C 5 (6%)
Country
- China 80 (93%)
- United States 1 (1%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
WABO Technology
|
WABO Technology operates as a non-invasive brain-computer interface developer focused on building task-conditioned neural intent models that translate human brain activity into standardized machine instructions. The company's core business model revolves around developing an integrated Hardware, AI, Interface, and Data (HAID) systemarchitecture to capture neural data and power its Neural Intent Data Platform. Their primary value proposition is delivering robust intent-understanding capabilities that allow humans to naturally control, correct, and communicate with embodied robotics, spatial computing setups, and intelligent environments without relying on traditional screens or intrusive surgical implants. | Angel / Jul 29, 2026 | |
DUCO
|
DUCO is a Chinese company specializing in the development and manufacturing of collaborative robots (cobots). The company focuses on creating robotic solutions for various industrial applications. DUCO offers a variety of cobots with payload capacities ranging from 3 kg to 30 kg and arm reaches between 618 mm and 2000 mm. These robots are designedfor tasks such as assembly, welding, machine tending, inspection, and testing. | Series A / Jul 08, 2026 | |
Bose Quantum
|
Bose Quantum has the patent layout and core technology of quantum computing technology comparable to that of the United States. The scientific research achievements in the field of quantum computing are currently the only solution with short-term commercialization feasibility in the world, creating a new generation of quantum computing poweracceleration for artificial intelligence. Artificial intelligence co-processing equipment to achieve megabit ultra-large-scale quantum computing. The Bose Quantum team has completed the CIM engineering prototype verification of 1000+ qubits abroad, and has stably running some accelerated algorithms. The technical advantages of Bose Quantum are reflected in the fact that the CIM technology solution adopted is the most advanced second-generation optical quantum computing technology, which is the most advanced quantum computing technology route in the three major mainstream scalable quantum computing technology routes of superconductivity, ion trap and optical quantum. The largest technical solution. | Venture - Series Unknown / Jul 03, 2026 | |
Sand.ai
|
Sand AI is an AI company that focuses on producing videos. | Series B / Jun 22, 2026 | |
Huaqing Weiyang
|
Huaqing Weiyang is a large-scale machine language model platform that provides intelligent solutions for software function development with AI technology to empower cyberspace. | $14.8M / Seed / Jun 01, 2026 | |
|
Zhongke Tiansuan
|
Zhongke Tiansuan is a provider of space-based intelligent computing and application systems. | $14.5M / Angel / Mar 12, 2026 | |
Beta Infinite
|
Beta Infinite approaches data and model technologies in a distinctive and distinctive way. | $14.5M / Seed / Mar 10, 2026 | |
Regend Therapeutics
|
Regend Therapeutics focuses on the human organ regenerative medicine business and is a global leader in this field. Its core product REGEND001 cell preparation has been accepted by the State Food and Drug Administration and is the world's first autologous stem cell product for respiratory diseases. The company is also the first company inChina to be registered by the National Health and Health Commission and the Food and Drug Administration, and is allowed to conduct clinical research on stem cells (Registration No.: CMR-20161214-1002). It is also the first batch of key research and development programs of the Ministry of Science and Technology. And companies that transform research topics. At present, the company has passed ISO9001:2008 quality management system certification, and the stem cell preparation has passed the China Metrology Accreditation (CMA), China Conformity Assessment Committee (CNAS) and IAF International Mutual Recognition. All clinical programs of Jimmy Suisheng are strictly in accordance with the regulations of the National Health Care Commission and the Food and Drug Administration, and are registered with the National Trial Global Database of the National Institutes of Health. | $50.6M / Series C / Feb 11, 2026 | |
|
liko.ai
|
Lido.ai focuses on designing an AI Home Center and AI-native cameras using NPU and edge-side large models, with a vision of creating a home AI butler system that understands, protects, and empathizes with its users. | Seed / Jan 06, 2026 | |
SNBT
|
SNBT is a satellite communication service provider specializing in industrial-scale satellite communication and networking, delivering reliable, high-performance connectivity solutions that support mission-critical operations across sectors such as energy, transportation, remote infrastructure, defense, and large-scale enterprise networks. | $56.7M / Series C / Dec 12, 2025 | |
| See all 86 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Angel Plus China invest in?
Angel Plus China invests primarily in Software, Artificial Intelligence and Information Technology startups, most often at Angel and Series A stage. Most of the 86 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Angel Plus China's check size?
Angel Plus China typically joins rounds of $71k–$120M at Seed, $425k–$2.8M at Angel and $1.4M–$16M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Angel Plus China participates in.
When did Angel Plus China last invest?
The most recent investment recorded for Angel Plus China closed in Jul 2026. Shizune tracks 86 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
